Side-by-side · Research reference

N-Acetyl Epitalon AmidatevsOvagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited

BTheoreticalHUMAN-REVIEWED2/42 cited

N-Acetyl Epitalon Amidate

Bioregulator Tetrapeptide · Khavinson School

10 passagesExtra divisionsKhavinson 2004

Telomerase+Enzyme inductionKhavinson 2003

4-AATetrapeptide

SQ · Variable protocols

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

01Mechanism of Action

Parameter

N-Acetyl Epitalon Amidate

Ovagen

Primary target

DNA promoter regions (telomerase, RNA polymerase II, retinal genes)

Ovarian tissue chromatin complexes

Pathway

Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Downstream effect

Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003 Khavinson 2004

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Feedback intact?

—

Presumed physiological — Khavinson peptides described as regulatory, not replacement

Origin

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Antibody development

—

02Dosage Protocols

Parameter

N-Acetyl Epitalon Amidate

Ovagen

Standard dose

No standardized human dosing in indexed literature

In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

Frequency

Not specified in candidate papers

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Evidence basis

In vitro human cell cultureKhavinson 2004 Khavinson 2003

Theoretical / Russian-tradition

Cell culture protocol

Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004

Cells made 10 extra divisions (44 passages total vs 34 in control).

—

Duration

Chronic treatment in aging culture

Sustained effect through late passages.

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

Modification stability

N-acetyl + C-amide caps enhance peptidase resistance

Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.

—

Route

—

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

04Side Effects & Safety

Parameter

N-Acetyl Epitalon Amidate

Ovagen

Human safety data

Not available in indexed literature

Candidate papers describe in vitro and animal models only.

—

Theoretical telomerase risk

Telomerase activation in somatic cells raises theoretical oncogenic transformation concern

—

In vitro observations

No cytotoxicity reported in human fetal fibroblast cultureKhavinson 2004

—

Reported adverse events

—

None documented in indexed literature

Theoretical hormonal effects

—

Ovarian stimulation — monitor for estrogen-sensitive conditions

Injection site reaction

—

Possible mild erythema (SQ route)

Long-term safety

—

Unknown — no PubMed-indexed RCTs

Absolute Contraindications

N-Acetyl Epitalon Amidate

·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Relative Contraindications

N-Acetyl Epitalon Amidate

·Individuals with hereditary cancer syndromes or high genetic cancer risk

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

05Administration Protocol

Parameter

N-Acetyl Epitalon Amidate

Ovagen

1. Route

Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

2. Reconstitution

Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

3. Storage

Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

4. Clinical protocols

Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

06Stack Synergy

N-Acetyl Epitalon Amidate

+ Thymalin

Moderate

View Thymalin →

Both are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.

Epitalon: Protocol not defined in indexed literature
Thymalin: Tissue-specific bioregulator · separate dosing
Rationale: Complementary transcriptional targets
Primary benefit: Dual-axis aging intervention: cellular senescence + immune restoration

Ovagen

— no documented stacks